greeksoup/ stock research

Pennant Group, Inc.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 25 February 2026: press release. Guidance figures: 7 new, 1 kept. The quarter’s numbers.

Key takeaways

  • Full-year revenue rose 36.3%: Full-year 2025 total revenue was $947.7 million, up $252.5 million or 36.3%. Fourth-quarter revenue was $289.3 million, up 53.2% on the prior-year quarter. Source
  • Net income and EPS rose: Full-year GAAP diluted EPS was $0.84 and adjusted diluted EPS was $1.18. Fourth-quarter GAAP diluted EPS was $0.24 and adjusted diluted EPS was $0.34. Source
  • Home health and hospice revenue up 41.0%: Home Health and Hospice Services revenue was $732.7 million for the full year, up 41.0%, and $233.3 million for the fourth quarter, up 64.3%. Source
  • Medicare home health admissions up 41.8%: Medicare home health admissions were 34,882 for the full year, up 41.8%, and 12,082 for the fourth quarter, up 87.5%. Source
  • Hospice census up 28.6%: Hospice average daily census was 4,204 for the full year, up 28.6%, and 5,060 for the fourth quarter, up 46.9%. Source
  • Acquired assets shown in guidance: The 2026 guidance includes revenue and adjusted EBITDA from the former UnitedHealth and Amedisys assets, shown separately from the rest of the business. Source

“2025 was a year of record-breaking performance and growth for Pennant”

Brent Guerisoli, the Company’s Chief Executive Officer

Guidance

AreaPeriodFigureAgainst last quarter
Total revenue Sourcefull year 2026$1,133.6 million to $1,171.8 millionNew
Adjusted earnings per diluted share Sourcefull year 2026$1.26 to $1.36New
Adjusted EBITDA Sourcefull year 2026$88.5 million to $94.1 millionNew
Adjusted EBITDA prior to NCI Sourcefull year 2026$94.2 million to $100.0 millionNew
Diluted weighted average shares Sourcefull year 2026approximately 37.0 million
Effective tax rate Sourcefull year 202626.0%Kept
Revenue from former UnitedHealth and Amedisys assets Sourcefull year 2026$191.2 million to $200.3 millionNew
Adjusted EBITDA from former UnitedHealth and Amedisys assets Sourcefull year 2026$16.7 million to $17.9 millionNew
Adjusted EBITDA prior to NCI from former UnitedHealth and Amedisys assets Sourcefull year 2026$19.8 million to $21.1 millionNew

What changed from last quarter

  • New guidance: Management provided 2026 annual guidance; the third-quarter release had provided 2025 annual guidance. Source
  • New: Guidance now shows revenue and adjusted EBITDA for the former UnitedHealth and Amedisys assets separately. Source
  • Guidance kept: The 26.0% effective tax rate assumption is the same as in the third-quarter release. Source

Results and growth drivers

  • Full-year revenue rose 36.3%: Full-year 2025 total revenue was $947.7 million, up $252.5 million or 36.3%. Fourth-quarter revenue was $289.3 million, up 53.2% on the prior-year quarter. Source
  • Net income and EPS rose: Full-year GAAP diluted EPS was $0.84 and adjusted diluted EPS was $1.18. Fourth-quarter GAAP diluted EPS was $0.24 and adjusted diluted EPS was $0.34. Source
  • Net income rose 31.1%: Net income was $29.6 million for the full year, up 31.1%, and $8.6 million for the fourth quarter, up 50.0%. Source
  • Consolidated Adjusted EBITDA rose 36.0%: Consolidated Adjusted EBITDA was $72.5 million for the full year, up 36.0%, and $22.4 million for the fourth quarter, up 62.5%. Source

Segments and regions

  • Home health and hospice revenue up 41.0%: Home Health and Hospice Services revenue was $732.7 million for the full year, up 41.0%, and $233.3 million for the fourth quarter, up 64.3%. Source
  • Segment adjusted EBITDA up 37.8%: Home Health and Hospice segment adjusted EBITDA from operations was $111.1 million for the full year, up 37.8%. The fourth quarter was $33.7 million, up 58.2%. Source
  • Senior Living revenue up 22.3%: Senior Living Services revenue was $215.0 million for the full year, up 22.3%, and $56.1 million for the fourth quarter, up 19.6%. Source
  • Senior living occupancy rose 200 basis points: Fourth-quarter senior living occupancy was 80.6%, up 200 basis points. Average monthly revenue per occupied room was $5,238, up 5.6%. Source

“We saw tremendous momentum across virtually all key growth metrics in 2025”

John Gochnour, the Company’s Chief Operating Officer

Products, volumes and payors

  • Medicare home health admissions up 41.8%: Medicare home health admissions were 34,882 for the full year, up 41.8%, and 12,082 for the fourth quarter, up 87.5%. Source
  • Hospice census up 28.6%: Hospice average daily census was 4,204 for the full year, up 28.6%, and 5,060 for the fourth quarter, up 46.9%. Source
  • Same-agency revenue up 11.4%: Same-agency home health and hospice revenue was $518.0 million for the full year, up 11.4%, against $465.1 million in 2024. Source
  • Managed care share of revenue rose: Managed care revenue was $142.4 million for the full year, 15.0% of revenue, against 13.3% in 2024. Source

Costs, margins and pricing

  • Cost of services increased: Full-year cost of services was $768.5 million, against $558.4 million. Fourth-quarter cost of services was $237.1 million, against $152.7 million. Source
  • General and administrative expense rose: General and administrative expense was $71.1 million for the full year, against $50.2 million, and $19.3 million in the fourth quarter, against $13.9 million. Source
  • Consolidated Adjusted EBITDAR up 26.2%: Consolidated Adjusted EBITDAR was $120.9 million for the full year, up 26.2%, and $35.3 million for the fourth quarter, up 41.7%. Source
  • Medicare revenue per episode up 3.5%: Average Medicare revenue per 60-day completed episode was $3,755 for the full year, up 3.5% from $3,628. Source

“We believe providing updated annual adjusted consolidated EBITDA guidance in addition to updated annual revenue and adjusted earnings per share guidance is helpful”

Lynette Walbom, the Company’s Chief Financial Officer

Capital and cash flow

  • Operating cash flow rose: Net cash provided by operating activities was $48.3 million for the full year, against $39.3 million in 2024. Source
  • Investing outflow increased: Net cash used in investing activities was $228.0 million for the full year, against $70.7 million in 2024. Source
  • Borrowing funded the cash shortfall: Net cash provided by financing activities was $172.5 million for the full year. Long-term debt was $168.8 million at year-end, against none at December 31, 2024. Source

Strategy and transition

  • Acquired assets shown in guidance: The 2026 guidance includes revenue and adjusted EBITDA from the former UnitedHealth and Amedisys assets, shown separately from the rest of the business. Source
  • Southeast expansion foundation created: Management said the transaction created a foundation for additional expansion in the Southeast. Source
  • Operational flywheel gaining momentum: Management said the operational flywheel continues to gain momentum even while the company expands through acquisitions. Source

People and leadership

  • Seasoned leaders anchor 2026 efforts: Management said seasoned leaders and well-performing operations anchor the company's efforts, and the company is poised to continue this success in 2026. Source
  • Transitions alongside clinical performance: Management said the company worked to transition many new operations while delivering operational and clinical performance in both segments. Source
  • Acquisition transition experience cited: The Chief Operating Officer said the company has completed many acquisitions and understands the importance of successful transitions for employees, culture and results. Source

Non-GAAP adjustments

  • Non-GAAP net income reconciled: Non-GAAP net income was $41.6 million for the full year, against $30.0 million, after adjustments for start-up costs, share-based compensation and acquisition costs. Source
  • Transition services fees disclosed: Fees under the transition services agreement with UnitedHealth were $3.0 million for the full year, and are included in the non-GAAP adjustments. Source
  • Acquisition costs excluded from adjusted results: Acquisition related costs were $6.6 million for the full year, against $1.3 million, and $1.1 million in the fourth quarter. They are excluded from adjusted measures. Source

Coming up, as management said on 25 February 2026

  • Form 10-K to follow: Management said more complete information will be in the Form 10-K for 2025, which will be filed with the SEC. Source

Figures management reported

FigureReported
Patient volumes: total home health admissions Source86,076 for the full year, up 44.1%
Patient volumes: hospice average daily census Source4,204 for the full year, up 28.6%
Same-facility revenue: same agency home health and hospice Source$518.0 million for the full year, up 11.4%
Same-facility revenue: same store senior living Source$180.6 million for the full year, up 8.8%

Risks management discussed

  • Operational: Management named integration of the new operations as a 2026 focus, alongside operational excellence across the businesses. Source
  • Regulatory: Guidance assumes reimbursement rate adjustments, certain transition services agreement costs, and no unannounced acquisitions. Source

Earlier plans management reported on

  • Not stated: The third-quarter release said these operations would be in a transitional phase in the fourth quarter; this release says the company worked to transition many new operations.
  • Not stated: The third-quarter release gave a full-year 2025 adjusted EBITDA range; this release reports the full-year 2025 result.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.